ArriVent BioPharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '25 Oct 6, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	809	898	-	-	-
Enterprise Value	574	615	-	-	-
Last Close Price	19.95	26.64	-	-	-
PB Ratio	2.99	3.48	-	-	-
P/TBV Ratio	3.24	3.48	-	-	-
Debt / Equity Ratio	0	0.00	0.00	0.00	-
Quick Ratio	12.03	12.70	13.00	19.60	20.64
Current Ratio	12.74	13.14	13.76	21.85	23.63
Return on Equity (ROE)	-50.06%	-39.36%	-42.57%	-34.22%	-
Return on Assets (ROA)	-23.41%	-26.91%	-26.95%	-20.42%	-
Return on Capital (ROIC)	-24.76%	-28.79%	-28.58%	-21.38%	-
Earnings Yield	-16.90%	-8.97%	-	-	-
Buyback Yield / Dilution	-113.42%	-1369.88%	-67.64%	-79.57%	-

Updated Aug 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q